DS
EFTR

David Shaw’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

David Shaw’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,674
Closed -$1.65M – 5318
2021
Q2 		$1.65M Buy
+6,674
New +$1.64M ﹤0.01% 3134

Other funds holding EFTR

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CG
Column Group San Francisco, California $88.1M AUM 148.03% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $143M AUM 102.52% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

David Shaw's EFTR Position: Q3 2021 in Review

David Shaw sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2021, closing a stake of 6,674 shares — an estimated $1.65M sold.

David Shaw first reported a position in EFTR in Q2 2021 and held it in 1 quarter. The position peaked at $1.65M in Q2 2021. 12 funds tracked by Wall St. Rank hold EFTR as of Q3 2021.

  • David Shaw reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2021 after selling out during the quarter.
  • David Shaw sold 6,674 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2021, an estimated $1.65M.
  • David Shaw first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q2 2021 and held it in 1 quarter.
  • David Shaw's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $1.65M in Q2 2021.
  • 12 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2021.

Based on D.E. Shaw & Co's 13F filing for Q3 2021, filed 15 Nov 2021.